Comparing Tickers & Gains - 14.14% for AVGO (Day Trader) vs 14.62% for NVAX (Swing Trader)
Analyzing Ticker Performance: AVGO vs NVAX and Compare Day Trader: Medium Volatility Stocks for Active Trading (TA&FA) 14.14% for AVGO vs Swing Trader: Medium Volatility Stocks for Active Trading (TA&FA) 14.62% for NVAX
When comparing the tickers AVGO and NVAX, it is evident that both stocks have shown impressive gains. AVGO recorded a gain of 14.14%, while NVAX outperformed slightly with a gain of 14.62%. These figures indicate that both stocks have experienced notable growth, making them attractive options for traders.
Now let's delve deeper into the price growth of these stocks and explore the industries they belong to.
Price Growth Analysis:
AVGO, which operates in the semiconductor industry, witnessed a significant price change of +9.85% during the past week. On the other hand, NVAX, operating in the biotechnology sector, had a price change of +4.81% over the same period. These numbers highlight the robust performance of both companies in their respective industries.
Industry Comparison:
The average weekly price growth for all stocks in the semiconductor industry stood at +3.49%. Looking at the monthly average, the semiconductor industry demonstrated even stronger growth with +20.60%, while the quarterly average was +28.40%. These statistics indicate a consistently positive trend for semiconductor stocks, including AVGO.
In the biotechnology industry, the average weekly price growth across all stocks was +2.15%. The monthly average for the industry was +7.69%, and the quarterly average reached an impressive +40.61%. These numbers suggest that the biotechnology sector, where NVAX operates, also experienced steady growth during the measured period.
Earnings Reporting:
Investors closely monitor earnings reports as they provide crucial insights into a company's financial health. AVGO is expected to report earnings on September 7, 2023, while NVAX's earnings report is anticipated on August 3, 2023. Traders and investors should mark these dates on their calendars to stay updated on the financial performance of these companies.
Industry Descriptions:
The semiconductor industry (@Semiconductors) exhibited a weekly average price growth of +3.49%. This sector is known for its involvement in manufacturing electronic components, including integrated circuits and transistors. The positive weekly price growth indicates a favorable environment for semiconductor stocks.
The biotechnology industry (@Biotechnology) recorded a weekly average price growth of +2.15%. Biotechnology companies focus on using living organisms or biological systems to develop products and technologies that have medical, agricultural, or industrial applications. The modest weekly price growth suggests steady progress within the biotechnology sector.
Both AVGO and NVAX have displayed strong performance, with gains of 14.14% and 14.62% respectively. AVGO, operating in the semiconductor industry, has shown a substantial price change, while NVAX, in the biotechnology sector, has also exhibited notable growth. Investors should closely monitor these stocks and consider their respective industry trends and earnings reporting dates to make informed investment decisions.
NVAX's RSI Oscillator ascends from oversold territory
The RSI Indicator for NVAX moved out of oversold territory on February 28, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 38 similar instances when the indicator left oversold territory. In of the 38 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVAX advanced for three days, in of 276 cases, the price rose further within the following month. The odds of a continued upward trend are .
NVAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on March 20, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NVAX as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NVAX turned negative on March 21, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for NVAX entered a downward trend on March 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.047). P/E Ratio (0.000) is within average values for comparable stocks, (66.086). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.907). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (1.620) is also within normal values, averaging (239.969).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a company which engages in development of novel recombinant vaccines
Industry Biotechnology